Last reviewed · How we verify
Tritanrix™-HepB/ Hiberix™
Tritanrix-HepB/Hiberix is a vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b.
Tritanrix-HepB/Hiberix is a vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b. Used for Protection against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children.
At a glance
| Generic name | Tritanrix™-HepB/ Hiberix™ |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating the body's immune system to produce antibodies against these pathogens, providing long-term immunity. The vaccine contains inactivated or attenuated forms of the pathogens, which are unable to cause disease but still trigger an immune response.
Approved indications
- Protection against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Vomiting
Key clinical trials
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants (PHASE2)
- Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines (PHASE3)
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine (PHASE3)
- Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen (PHASE2)
- Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
- Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
- Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tritanrix™-HepB/ Hiberix™ CI brief — competitive landscape report
- Tritanrix™-HepB/ Hiberix™ updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI